B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: The growing saga of the IGHV3 subgroup gene usage

28Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

The immunoglobulin heavy chain variable gene (IGHV) mutational status has been recognized as an important predictor of prognosis in chronic lymphocytic leukaemia (CLL) since 1999. More recently, other features of the B-cell receptor, such as stereotypy, have been identified as capable of refining the prognostic potential of IGHV status in the clinical assessment of CLL patients. In this context, different genes belonging to the IGHV3 subgroup, the most frequently used subgroup in CLL, have been shown to denote disease subsets that either display a bad prognosis (i.e. IGHV3-21, IGHV3-23) or are associated with particularly good clinical outcomes, including a highly stable/indolent clinical course, even prone to spontaneous regression (i.e. IGHV3-72, IGHV3-30). The present review focuses on the molecular and biological features of CLL-expressing specific genes belonging to the IGHV3 subgroup that are known to mark disease subsets with completely different clinical courses, and may be possibly related to CLL pathogenesis via antigen and/or superantigen involvement. © 2011 Blackwell Publishing Ltd.

Cite

CITATION STYLE

APA

Dal-Bo, M., Del Giudice, I., Bomben, R., Capello, D., Bertoni, F., Forconi, F., … Gattei, V. (2011, April). B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: The growing saga of the IGHV3 subgroup gene usage. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2010.08440.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free